Latest Shareholder Resolutions News

Viking Mines reports significant gold discoveries at its Riverina East Project, including a new large gold anomaly and high-grade drill intercepts, alongside a promising underground mining study at First Hit.

Infinity Lithium Corporation has decided against exercising its option on Dart Mining's gold and base metals projects, opting instead to concentrate on advancing its wholly owned Cobungra gold-silver project in Victoria.

The Takeovers Panel has mandated Emu NL to hold a new shareholder meeting after finding serious irregularities in the recent extraordinary general meeting, including share issuance timing and proxy voting issues.

Coolabah Metals Limited has closed its upsized $20 million public offer ahead of schedule due to strong investor demand, progressing its strategic acquisition of Broken Hill Mines Pty Ltd. The move consolidates key mining assets at Broken Hill and sets the stage for a significant corporate transformation.

The Takeovers Panel has declared unacceptable circumstances in Emu NL’s recent shareholder meeting, citing a controversial share placement and proxy voting issues that clouded the election outcome and board control.

EVE Health Group has successfully passed all shareholder resolutions at its recent General Meeting, paving the way for its acquisition of Nextract Pty Ltd and announcing significant leadership changes.

Emu NL’s recent shareholder meeting saw all attempts to remove or elect new directors decisively rejected, reinforcing board stability as the company completes a planned capital raise.

G8 Education reported a robust 2024 financial and operational performance at its 2025 AGM, highlighting strategic progress and cautious optimism for 2025 despite early occupancy headwinds.

Cassius Mining Limited reports significant progress on its Soalara Limestone Project in Madagascar, initiates joint venture talks, and advances a major arbitration case against Ghana, while raising $1 million in fresh capital.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.